Trial Profile
A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Rogaratinib (Primary) ; Docetaxel; Paclitaxel; Vinflunine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORT-1
- Sponsors Bayer
- 14 Oct 2022 Results published in the Journal of Clinical Oncology
- 26 Nov 2020 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.